SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (204)12/1/2000 12:29:52 PM
From: Jim Oravetz  Read Replies (1) of 226
 
Matrix Pharm Pdt Cuts, Destroys Tumors In Liver Cancer
Dow Jones Newswires
CHICAGO -- Matrix Pharmaceutical Inc. (MATX) reported "encouraging" results in an ongoing Phase II study of IntraDose, an injectable gel used to treat patients with inoperable primary and secondary liver cancer.
In a press release Wednesday, the pharmaceutical company said patients in the study received four to eight weekly treatments of IntraDose, and a 55% of the patients had a 50% reduction in viable tumor.
IntraDose is injected directly into tumors, localizing high concentrations a chemotherapy agent, cisplatin, in the tumor.
The use of imaging techniques and ultrasound to precisely place injection into liver tumors is being researched.
Side effects of IntraDose include pain, transient hypertension and increased pulse rate. Infrequently, the treatment caused bleeding from the tumor or worsening liver function.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News